Introduction
The London Life Sciences Prospective Population Study (abbreviated to the “LOLIPOP study” or “LOLIPOP”) is a major UK research study investigating the mechanisms underlying heart disease stroke, diabetes, obesity and other major medical problems.
The LOLIPOP study is based at Ealing Hospital in West London, and at Imperial College London. We work in close collaboration with a number of major UK and overseas institutions, including Oxford, Cambridge, University College and Harvard Universities, deCODE Genetics and the Beijing Genomics Institute.
![]() The University of Surrey joined the LOLIPOP team in 2011, with the aim of providing a follow-up of the cohort. This will be done by collecting routine health care data (primary and secondary) for all of the patients that have agreed to participate in this study. All of the data will be held in an anonymised format at the University of Surrey’s secure servers. The purpose of this follow-up is to find any cases of cardiovascular disease in the cohort, after 10 years, which will help the team better understand the underlying mechanisms of these conditions. In order to receive health information, including hospital admissions and cause of death data, participants identifiable data is supplied to the Health and Social Care Information Centre and the Office for National Statistics. For more information regarding the University of Surrey’s involvement in this project, please contact Professor Simon de Lusignan (s.lusignan@surrey.ac.uk) or your doctor. If you are a member of the LOLIPOP cohort, and would like to opt out of your data being collected, please visit the Withdrawal section of this website. |